Latest Conference Articles

July 31st 2021, 1:00pm

International Lung Cancer Congress

Osimertinib has emerged as the standard of care for patients with EGFR-mutated non–small cell lung cancer, but the need for novel agents is underscored as disease progression on the agent is inevitable.

July 31st 2021, 1:00pm

International Lung Cancer Congress

David R. Gandara, MD, discusses how minimal residual disease testing might be incorporated into lung cancer clinical practice.

July 31st 2021, 12:00pm

International Lung Cancer Congress

Sukhmani K. Padda, MD, discusses strategies to overcome EGFR resistance in patients with non–small cell lung cancer.

July 30th 2021, 10:16pm

International Congress on the Future of Breast Cancer West

Neoadjuvant and adjuvant treatment with CDK4/6 inhibitors has shown encouraging preliminary evidence in patients with estrogen receptor–positive, HER2-negative breast cancer, but confirmation of durable benefit is needed in the adjuvant setting before they are brought into routine clinical practice.

July 30th 2021, 9:38pm

International Lung Cancer Congress

Bispecific antibodies have become an interesting new class of agents in the lung cancer pipeline, most recently with the developments of amivantamab-vmjw, zenocutuzumab, and tarlatamab.

July 30th 2021, 7:57pm

International Lung Cancer Congress

Sukhmani K. Padda, MD, discusses treatment selection following osimertinib resistance in patients with non–small cell lung cancer.

July 30th 2021, 6:40pm

International Lung Cancer Congress

Strategies focused on improving the efficacy of the EGFR tyrosine kinase inhibitor osimertinib in the first line setting are the key to unlocking the next wave of success in treating lung cancer.

July 30th 2021, 6:30pm

International Lung Cancer Congress

Sandip P. Patel, MD, discusses the potential of combining PARP inhibitors with immunotherapy for patients with non–small cell lung cancer.

July 30th 2021, 5:13pm

International Lung Cancer Congress

RET inhibitors displayed promising efficacy and a tolerable safety profile in patients with non–small cell lung cancer harboring RET alterations.

July 29th 2021, 9:41pm

International Lung Cancer Congress

Harmeet S. Bedi, MD, discusses the important role of pulmonologists in the diagnosis and management of patients with lung cancer.

July 29th 2021, 9:00pm

International Lung Cancer Congress

Although the predictive utility of minimal residual disease has yet to be fully realized in non–small cell lung cancer, it has the potential to guide treatment decisions in earlier lines of treatment, including the adjuvant setting.

July 27th 2021, 5:00pm

ASCO Direct Highlights

Insights generated from several trials presented during the 2021 ASCO Annual Meeting in renal cell carcinoma illustrate the importance of evaluating checkpoint inhibitors in earlier stages of disease, quality of life, and long-term outcomes, and other data that point to 2 potential new standards of care in prostate cancer.

July 23rd 2021, 1:00pm

ASCO Direct Highlights

Data presented during the 2021 ASCO Annual Meeting offered insight into the optimization of BTK inhibitors, induction therapy, consolidative therapy, and radiation therapy for patients across the paradigm of hematologic malignancies.

July 19th 2021, 8:40pm

International Congress on the Future of Breast Cancer East

The future of therapeutic vaccines in breast cancer will be dependent on their use in combination with standard anticancer drugs, checkpoint antagonists, and distinct checkpoint inhibitors, Leisha A. Emens, MD, PhD.

July 19th 2021, 8:22pm

International Congress on the Future of Breast Cancer East

Sara M. Tolaney, MD, MPH, discusses tailoring HER2-directed therapies in the treatment of patients with breast cancer. 

July 19th 2021, 7:28pm

International Congress on the Future of Breast Cancer East

Selective estrogen receptor degraders are becoming increasingly important in the treatment of ER-positive metastatic breast cancer.

July 17th 2021, 10:00am

International Congress on the Future of Breast Cancer East

Chemoimmunotherapy combinations have transformed the treatment landscape for patients with triple-negative breast cancer, but balancing potential efficacy with the risk of toxicity with these regimens is critical in both the metastatic and early-stage settings.

July 16th 2021, 8:15pm

International Congress on the Future of Breast Cancer East

By adapting adjuvant therapy based on responses to preoperative therapy, investigators may be able to change long term outcomes for patients with HER2-positive breast cancer, creating a paradigm shift in the space.

July 12th 2021, 9:01pm

European Association of Urology Congress

Vinayak G. Wagaskar, MBBS, discusses potential explanations for a paradoxical relationship between obesity and outcomes observed in prostate cancer.

July 12th 2021, 8:57pm

European Association of Urology Congress

Evangelia Sereti, MSc, PhD, discusses the next steps with the combination of NOV202 and olaparib in BRCA1/2-mutated prostate cancer.